Chemoterapeutic drug screening based on patient?derived pancreatic cancer xenograft(PDX)models
10.3969/j.issn.1005-4847.2018.01.005
- VernacularTitle:基于胰腺癌患者来源异种移植模型的化疗药物筛选
- Author:
He ZHANG
1
;
Xue CHEN
;
Caiqin ZHANG
;
Yong ZHAO
;
Dengxu TAN
;
Changhong SHI
Author Information
1. 第四军医大学实验动物中心
- Keywords:
pancreatic carcinoma;
patient-derived xenograft(PDX)model;
individualized treatment;
drug screening;
TGD mathematic model;
nude mice
- From:
Acta Laboratorium Animalis Scientia Sinica
2018;26(1):29-35
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the therapeutic effect of chemotherapeutic drugs on pancreatic carcinoma based on patient-derived xenograft(PDX)models,and to screen an individualized treatment strategy. Methods Fresh human pancreatic carcinoma tissues were subcutaneously transplanted into nude mice to establish PDX models which could be stab-ly passaged. The traceability of PDX models was determined by STR analysis. The PDX models were treated with three dif-ferent clinical chemotherapeutic drugs oxaliplatin, gemcitabine and irinotecan, respectively, and the tumor volumes were measured at different times. The therapeutic effect of those drugs was assessed by TGD mathematical model and plasma CA19-9 test. Results The traceability of patient-derived xenograft samples was up to 99.99%. Compared with the con-trol group,the treatment with irinotecan and gemcitabine inhibited tumor growth significantly(P=0.001), and gemcit-abine had even better result. The minimum toxic effect in the mice was induced by irinotecan treatment,followed by gem-citabine treatment. Conclusions Pancreatic carcinoma PDX models are successfully established and can be stably pas-saged. Gemcitabine shows the most inhibitory effect on tumor growth based on TGD mathematical model assessment, and deserves to be recommended as the preferred drug for individual treatment of pancreatic carcinoma.
